Section Arrow
BLTE.NASDAQ
- Belite Bio
Quotes are at least 15-min delayed:2026/02/23 18:20 EST
After Hours
Last
 189.7
+1.79 (+0.95%)
Bid
187.82
Ask
189.7
High 189.7 
Low 189.26 
Volume 514 
Regular Hours (Closed)
Last
 187.91
+6.96 (+3.85%)
Day High 
191.5 
Prev. Close
180.95 
1-M High
200 
Volume 
158.52K 
Bid
187.82
Ask
189.7
Day Low
180.95 
Open
180.95 
1-M Low
155 
Market Cap 
6.79B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 178.32 
20-SMA 175.15 
50-SMA 163.35 
52-W High 200 
52-W Low 49 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.92/0.06
Enterprise Value
6.79B
Balance Sheet
Book Value Per Share
7.31
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
GOSSGossamer Bio0.42055-1.70945-80.26%-- 
After Hours 0.4093 -0.01125 -2.68%
IBRXImmunityBio9.82+1.12+12.87%-- 
After Hours 9.83 +0.01 +0.10%
VNDAVanda Pharmaceuticals8.17+2.41+41.84%-- 
After Hours 8.34 +0.17 +2.08%
IKTInhibikase Therapeutics1.8+0.04+2.27%3.74PE
After Hours 1.8502 +0.0502 +2.79%
KLTOKlotho Neurosciences Inc0.41+0.1573+62.25%-- 
After Hours 0.385 -0.025 -6.10%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.